- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07697248
LRG GIST Patient Registry
8. juli 2026 opdateret af: The Life Raft Group
Life Raft Group GIST Registry Protocol
The Life Raft Group (LRG) Patient Registry is a structured database that collects comprehensive information about individuals diagnosed with GIST.
The purpose of this registry is to facilitate research, improve understanding of the disease, track patient outcomes, and ultimately enhance patient care.
Studieoversigt
Status
Rekruttering
Detaljeret beskrivelse
An organization called the Life Raft Group (LRG) wants to find out more about a cancer called Gastrointestinal Stromal Tumors (GIST) as well as other cancers that may or may not be related to GIST.
To collect this information, LRG has created a research registry.
A registry is a place where medical information, family history and other related information from patients is collected and stored for medical research.
The purpose of the Life Raft Group GIST registry is to collect and store medical information and other information from individuals with the same disease or other cancers that share commonalities such as molecular targets, treatments, or other factors.
Information from patients in this registry will be used for medical research to better understand GIST and these other diseases.
Scientists studying GIST and these other diseases need more accurate, real-world information to understand how these diseases affect people.
People with GIST and other related or unrelated diseases are being asked if they would like to participate in the Life Raft Group registry.
The Life Raft Group GIST registry is also linked to a tissue bank, which is a place that stores tumor tissue, blood or other samples from patients.
Participants may also be asked to provide samples to the tissue bank.
Participants would need to read and sign a separate consent form about the tissue bank.
Participants do not have to take part in any other Life Raft Group activities, including the tissue bank and online forums, to take part in this registry.
Undersøgelsestype
Observationel
Tilmelding (Anslået)
5000
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiekontakt
- Navn: Patient Registry Department
- Telefonnummer: 973-837-9092
- E-mail: patientregistrydepartment@liferaftgroup.org
Studiesteder
-
-
New Jersey
-
Wayne, New Jersey, Forenede Stater, 07470
- Rekruttering
- The Life Raft Group
-
Kontakt:
- Telefonnummer: 973-837-9092
- E-mail: patientregistrydepartment@liferaftgroup.org
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
- Barn
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Ingen
Prøveudtagningsmetode
Ikke-sandsynlighedsprøve
Studiebefolkning
Gastrointestinal Stromal Tumor diagnosis
Beskrivelse
Inclusion Criteria:
- Gastrointestinal Stromal Tumor diagnosis
- Provide written and informed consent
Exclusion Criteria:
-
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Overall survival
Tidsramme: From the date of registry enrollment until death from any cause, assessed through follow-up for up to 25 years.
|
Time from registry enrollment until death from any cause.
|
From the date of registry enrollment until death from any cause, assessed through follow-up for up to 25 years.
|
|
Progression Free Survival
Tidsramme: From the date of registry enrollment until the first documented disease progression or death from any cause, whichever occurs first, assessed through follow-up for up to 25 years.
|
Time from registry enrollment until documented disease progression or death, whichever occurs first.
|
From the date of registry enrollment until the first documented disease progression or death from any cause, whichever occurs first, assessed through follow-up for up to 25 years.
|
|
Recurrence Free Survival
Tidsramme: From the date of complete surgical resection until the first documented recurrence of GIST or death from any cause, whichever occurs first, assessed through follow-up for up to 25 years.
|
Time from registry enrollment (or from complete surgical resection, if that is the clinically relevant starting point) until the first documented recurrence of GIST or death from any cause, whichever occurs first.
|
From the date of complete surgical resection until the first documented recurrence of GIST or death from any cause, whichever occurs first, assessed through follow-up for up to 25 years.
|
|
Disease Free Survival
Tidsramme: From the date of complete surgical resection until the first documented recurrence of GIST or death from any cause, whichever occurs first, assessed through follow-up for up to 25 years.
|
Disease-free survival is defined as the time from complete surgical resection of localized GIST until the first documented recurrence of GIST or death from any cause, whichever occurs first.
|
From the date of complete surgical resection until the first documented recurrence of GIST or death from any cause, whichever occurs first, assessed through follow-up for up to 25 years.
|
|
Time of Medication
Tidsramme: From the date of treatment initiation until permanent discontinuation of the medication for any reason, assessed through follow-up for up to 25 years.
|
Duration of treatment with a specific systemic therapy (e.g., imatinib, sunitinib, regorafenib, ripretinib), measured from treatment initiation until permanent discontinuation for any reason, including disease progression, toxicity, patient preference, or death.
|
From the date of treatment initiation until permanent discontinuation of the medication for any reason, assessed through follow-up for up to 25 years.
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Faktiske)
1. april 2013
Primær færdiggørelse (Anslået)
31. december 2099
Studieafslutning (Anslået)
31. december 2099
Datoer for studieregistrering
Først indsendt
1. juli 2026
Først indsendt, der opfyldte QC-kriterier
8. juli 2026
Først opslået (Faktiske)
13. juli 2026
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
13. juli 2026
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
8. juli 2026
Sidst verificeret
1. juli 2026
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- LRG2013PR112
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ingen
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med GIST
-
Indiana UniversityAfsluttet
-
Leiden University Medical CenterUkendt
-
European Organisation for Research and Treatment...Trukket tilbage
-
Chinese University of Hong KongFudan University; Asian Institute of Gastroenterology, India; Osaka International...RekrutteringGIST | Små gastrointestinale stromale tumorerJapan, Indien, Hong Kong, Kina
-
The First Affiliated Hospital with Nanjing Medical...RekrutteringGastrointestinal stromaltumor (GIST)Kina
-
Peking UniversityUkendt
-
PfizerAfsluttetGISTForenede Stater, Schweiz, Belgien, Danmark, Spanien, Det Forenede Kongerige, Australien, Indien, Frankrig, Slovakiet, Canada, Finland, Tyskland, Korea, Republikken, Holland, Polen
-
Kumquat Biosciences Inc.RekrutteringGIST | Gastrointestinale tumorer | GIST - Gastrointestinal Stromal Tumor | Gastrointestinal stromal tumor | GIST Metastatisk kræftForenede Stater
-
Blueprint Medicines CorporationGodkendt til markedsføring
-
Universität Duisburg-EssenIkke rekrutterer endnuGIST - Gastrointestinal Stromal Tumor | Gastrointestinal stromaltumor (GIST)Tyskland